search
Back to results

Effect of Metformin on Insulin Sensitivity and Pan-Arterial Vascular Function in Adults With Metabolic Syndrome (EJB044)

Primary Purpose

Metabolic Syndrome, Insulin Sensitivity

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Placebos
metformin
Sponsored by
University of Virginia
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Metabolic Syndrome

Eligibility Criteria

18 Years - 60 Years (Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Age 18-60

    • No smoking the past 6 months
    • Normal screening labs or no clinically significant values-except those listed below

    • Must have 3 of the following 4 characteristics established by NCEP-AHA-NHLBI

      • Males waist circumference greater than 40 inches, females greater than 35 inches
      • Blood pressure greater than 130/85 or on treatment with one or more antihypertensive agent
      • Fasting plasma triglycerides >150 or HDL <40 (males) <50 (females)
      • Fasting blood sugar >100 but <126

    • Subject may participate if on the following drugs, provided the drugs can remain at stable doses throughout the 12 week treatment interval.

      • Ace inhibitor
      • ARB
      • HMG CoA reductase inhibitor
      • Beta blocker
      • Calcium channel blockers
      • Alpha-adrenergic antagonist

Exclusion Criteria:

  • Smoking presently or in the past 6 months
  • HbA1c ≥ 6.5
  • Glucocorticoids-eg: prednisone, dexamethasone
  • Any known sensitivity or intolerance to Metformin
  • Any chronic GI disorders such as Irritable Bowel Syndrome or Crohns disease
  • History of congestive heart failure, ischemic heart disease, severe pulmonary disease, liver or kidney disease.
  • History of malignant or metabolic disorders including diabetes
  • Presence of an intracardiac or intrapulmonary shunt (we will screen for this by auscultation during the physical exam by PI)
  • Hypersensitivity to perflutren (contained in Definity)
  • Pregnant or breastfeeding

Sites / Locations

  • University of Virginia

Arms of the Study

Arm 1

Arm 2

Arm Type

Placebo Comparator

Experimental

Arm Label

Placebo

Metformin

Arm Description

12 weeks of Placebo tablet 3 x daily

12 weeks of Metformin tablet 850 mg 3 x daily

Outcomes

Primary Outcome Measures

Flow Mediated Dilation - Endothelial Function
brachial artery ultrasonography % flow-mediated dilatation (FMD) for assessing endothelial function before and after an insulin clamp to assess insulin's effect on the vasculature

Secondary Outcome Measures

Full Information

First Posted
September 26, 2014
Last Updated
March 9, 2020
Sponsor
University of Virginia
search

1. Study Identification

Unique Protocol Identification Number
NCT02633488
Brief Title
Effect of Metformin on Insulin Sensitivity and Pan-Arterial Vascular Function in Adults With Metabolic Syndrome
Acronym
EJB044
Official Title
Effect of Metformin on Insulin Sensitivity and Pan-Arterial Vascular Function in Adults With Metabolic Syndrome
Study Type
Interventional

2. Study Status

Record Verification Date
March 2020
Overall Recruitment Status
Completed
Study Start Date
June 2014 (undefined)
Primary Completion Date
July 2016 (Actual)
Study Completion Date
July 2016 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Virginia

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to look at how insulin (a hormone that helps the cells get energy from sugar) in our body affects blood vessels (elasticity in the bigger blood vessels and blood flow in the smaller blood vessels in the arm) and how Metformin (a drug that makes you more sensitive to insulin) affects insulin's action on the blood vessels.
Detailed Description
In our protocol, we will study vascular function using pulse wave velocity (PWV) augmentation index (AI), flow mediated dilation (FMD) and contrast enhanced ultrasound (CEU) as well as insulin sensitivity (euglycemic clamp) in 50 adults with metabolic syndrome, age 18-60 years. They will each be studied 4 times,before and after two 12-wk interventions (randomly assigned) as follows: 1) Placebos and 2) Metformin . This is a cross-over design.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Metabolic Syndrome, Insulin Sensitivity

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
Participant
Allocation
Randomized
Enrollment
19 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
12 weeks of Placebo tablet 3 x daily
Arm Title
Metformin
Arm Type
Experimental
Arm Description
12 weeks of Metformin tablet 850 mg 3 x daily
Intervention Type
Drug
Intervention Name(s)
Placebos
Other Intervention Name(s)
inactive substance
Intervention Description
A 12 week single blind placebos
Intervention Type
Drug
Intervention Name(s)
metformin
Other Intervention Name(s)
glucophage
Intervention Description
A 12 week single blind metformin
Primary Outcome Measure Information:
Title
Flow Mediated Dilation - Endothelial Function
Description
brachial artery ultrasonography % flow-mediated dilatation (FMD) for assessing endothelial function before and after an insulin clamp to assess insulin's effect on the vasculature
Time Frame
before and after 12 weeks on placebo or metformin

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age 18-60 No smoking the past 6 months Normal screening labs or no clinically significant values-except those listed below Must have 3 of the following 4 characteristics established by NCEP-AHA-NHLBI Males waist circumference greater than 40 inches, females greater than 35 inches Blood pressure greater than 130/85 or on treatment with one or more antihypertensive agent Fasting plasma triglycerides >150 or HDL <40 (males) <50 (females) Fasting blood sugar >100 but <126 Subject may participate if on the following drugs, provided the drugs can remain at stable doses throughout the 12 week treatment interval. Ace inhibitor ARB HMG CoA reductase inhibitor Beta blocker Calcium channel blockers Alpha-adrenergic antagonist Exclusion Criteria: Smoking presently or in the past 6 months HbA1c ≥ 6.5 Glucocorticoids-eg: prednisone, dexamethasone Any known sensitivity or intolerance to Metformin Any chronic GI disorders such as Irritable Bowel Syndrome or Crohns disease History of congestive heart failure, ischemic heart disease, severe pulmonary disease, liver or kidney disease. History of malignant or metabolic disorders including diabetes Presence of an intracardiac or intrapulmonary shunt (we will screen for this by auscultation during the physical exam by PI) Hypersensitivity to perflutren (contained in Definity) Pregnant or breastfeeding
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Eugene Barett, MD, PhD
Organizational Affiliation
University of Virginia
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Virginia
City
Charlottesville
State/Province
Virginia
ZIP/Postal Code
22903
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No
IPD Sharing Plan Description
Data will be reported as composite for the entire population. In some figures individual data point are displayed but not identified with individual subjects.
Citations:
PubMed Identifier
20228401
Citation
ACCORD Study Group; Cushman WC, Evans GW, Byington RP, Goff DC Jr, Grimm RH Jr, Cutler JA, Simons-Morton DG, Basile JN, Corson MA, Probstfield JL, Katz L, Peterson KA, Friedewald WT, Buse JB, Bigger JT, Gerstein HC, Ismail-Beigi F. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010 Apr 29;362(17):1575-85. doi: 10.1056/NEJMoa1001286. Epub 2010 Mar 14.
Results Reference
background
PubMed Identifier
20404853
Citation
Brown A, Reynolds LR, Bruemmer D. Intensive glycemic control and cardiovascular disease: an update. Nat Rev Cardiol. 2010 Jul;7(7):369-75. doi: 10.1038/nrcardio.2010.35. Epub 2010 Apr 20.
Results Reference
background
PubMed Identifier
20606150
Citation
Cooper-DeHoff RM, Gong Y, Handberg EM, Bavry AA, Denardo SJ, Bakris GL, Pepine CJ. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA. 2010 Jul 7;304(1):61-8. doi: 10.1001/jama.2010.884.
Results Reference
background
PubMed Identifier
10909983
Citation
Steinberg HO, Paradisi G, Hook G, Crowder K, Cronin J, Baron AD. Free fatty acid elevation impairs insulin-mediated vasodilation and nitric oxide production. Diabetes. 2000 Jul;49(7):1231-8. doi: 10.2337/diabetes.49.7.1231.
Results Reference
background
PubMed Identifier
9276741
Citation
Steinberg HO, Tarshoby M, Monestel R, Hook G, Cronin J, Johnson A, Bayazeed B, Baron AD. Elevated circulating free fatty acid levels impair endothelium-dependent vasodilation. J Clin Invest. 1997 Sep 1;100(5):1230-9. doi: 10.1172/JCI119636.
Results Reference
background
PubMed Identifier
14633847
Citation
Tripathy D, Mohanty P, Dhindsa S, Syed T, Ghanim H, Aljada A, Dandona P. Elevation of free fatty acids induces inflammation and impairs vascular reactivity in healthy subjects. Diabetes. 2003 Dec;52(12):2882-7. doi: 10.2337/diabetes.52.12.2882.
Results Reference
background
PubMed Identifier
15504968
Citation
de Jongh RT, Serne EH, Ijzerman RG, de Vries G, Stehouwer CD. Free fatty acid levels modulate microvascular function: relevance for obesity-associated insulin resistance, hypertension, and microangiopathy. Diabetes. 2004 Nov;53(11):2873-82. doi: 10.2337/diabetes.53.11.2873.
Results Reference
background
PubMed Identifier
19567533
Citation
Liu Z, Liu J, Jahn LA, Fowler DE, Barrett EJ. Infusing lipid raises plasma free fatty acids and induces insulin resistance in muscle microvasculature. J Clin Endocrinol Metab. 2009 Sep;94(9):3543-9. doi: 10.1210/jc.2009-0027. Epub 2009 Jun 30.
Results Reference
background
PubMed Identifier
11701689
Citation
Westerbacka J, Seppala-Lindroos A, Yki-Jarvinen H. Resistance to acute insulin induced decreases in large artery stiffness accompanies the insulin resistance syndrome. J Clin Endocrinol Metab. 2001 Nov;86(11):5262-8. doi: 10.1210/jcem.86.11.8047.
Results Reference
background
PubMed Identifier
10102699
Citation
Westerbacka J, Vehkavaara S, Bergholm R, Wilkinson I, Cockcroft J, Yki-Jarvinen H. Marked resistance of the ability of insulin to decrease arterial stiffness characterizes human obesity. Diabetes. 1999 Apr;48(4):821-7. doi: 10.2337/diabetes.48.4.821.
Results Reference
background
PubMed Identifier
7635973
Citation
Baron AD, Steinberg HO, Chaker H, Leaming R, Johnson A, Brechtel G. Insulin-mediated skeletal muscle vasodilation contributes to both insulin sensitivity and responsiveness in lean humans. J Clin Invest. 1995 Aug;96(2):786-92. doi: 10.1172/JCI118124.
Results Reference
background
PubMed Identifier
19283361
Citation
Barrett EJ, Eggleston EM, Inyard AC, Wang H, Li G, Chai W, Liu Z. The vascular actions of insulin control its delivery to muscle and regulate the rate-limiting step in skeletal muscle insulin action. Diabetologia. 2009 May;52(5):752-64. doi: 10.1007/s00125-009-1313-z. Epub 2009 Mar 13.
Results Reference
background
PubMed Identifier
8647954
Citation
Steinberg HO, Chaker H, Leaming R, Johnson A, Brechtel G, Baron AD. Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. J Clin Invest. 1996 Jun 1;97(11):2601-10. doi: 10.1172/JCI118709.
Results Reference
background
PubMed Identifier
15735211
Citation
Rossi R, Cioni E, Nuzzo A, Origliani G, Modena MG. Endothelial-dependent vasodilation and incidence of type 2 diabetes in a population of healthy postmenopausal women. Diabetes Care. 2005 Mar;28(3):702-7. doi: 10.2337/diacare.28.3.702.
Results Reference
background
PubMed Identifier
16781373
Citation
Goldfine AB, Beckman JA, Betensky RA, Devlin H, Hurley S, Varo N, Schonbeck U, Patti ME, Creager MA. Family history of diabetes is a major determinant of endothelial function. J Am Coll Cardiol. 2006 Jun 20;47(12):2456-61. doi: 10.1016/j.jacc.2006.02.045. Epub 2006 May 30.
Results Reference
background
PubMed Identifier
8074198
Citation
Baron AD. Hemodynamic actions of insulin. Am J Physiol. 1994 Aug;267(2 Pt 1):E187-202. doi: 10.1152/ajpendo.1994.267.2.E187.
Results Reference
background
PubMed Identifier
1874938
Citation
Baron AD, Laakso M, Brechtel G, Edelman SV. Mechanism of insulin resistance in insulin-dependent diabetes mellitus: a major role for reduced skeletal muscle blood flow. J Clin Endocrinol Metab. 1991 Sep;73(3):637-43. doi: 10.1210/jcem-73-3-637.
Results Reference
background
PubMed Identifier
2189893
Citation
Laakso M, Edelman SV, Brechtel G, Baron AD. Decreased effect of insulin to stimulate skeletal muscle blood flow in obese man. A novel mechanism for insulin resistance. J Clin Invest. 1990 Jun;85(6):1844-52. doi: 10.1172/JCI114644.
Results Reference
background
PubMed Identifier
1499861
Citation
Laakso M, Edelman SV, Brechtel G, Baron AD. Impaired insulin-mediated skeletal muscle blood flow in patients with NIDDM. Diabetes. 1992 Sep;41(9):1076-83. doi: 10.2337/diab.41.9.1076.
Results Reference
background
PubMed Identifier
8325979
Citation
Vollenweider P, Tappy L, Randin D, Schneiter P, Jequier E, Nicod P, Scherrer U. Differential effects of hyperinsulinemia and carbohydrate metabolism on sympathetic nerve activity and muscle blood flow in humans. J Clin Invest. 1993 Jul;92(1):147-54. doi: 10.1172/JCI116542.
Results Reference
background
PubMed Identifier
8572189
Citation
Raitakari M, Knuuti MJ, Ruotsalainen U, Laine H, Makea P, Teras M, Sipila H, Niskanen T, Raitakari OT, Iida H, Harkonen R, Wegelius U, Yki-Jarvinen H, Nuutila P, et al. Insulin increases blood volume in human skeletal muscle: studies using [15O]CO and positron emission tomography. Am J Physiol. 1995 Dec;269(6 Pt 1):E1000-5. doi: 10.1152/ajpendo.1995.269.6.E1000.
Results Reference
background
PubMed Identifier
9392489
Citation
Raitakari M, Nuutila P, Knuuti J, Raitakari OT, Laine H, Ruotsalainen U, Kirvela O, Takala TO, Iida H, Yki-Jarvinen H. Effects of insulin on blood flow and volume in skeletal muscle of patients with IDDM: studies using [15O]H2O, [15O]CO, and positron emission tomography. Diabetes. 1997 Dec;46(12):2017-21. doi: 10.2337/diab.46.12.2017.
Results Reference
background
PubMed Identifier
9628275
Citation
Tack CJ, Ong MK, Lutterman JA, Smits P. Insulin-induced vasodilatation and endothelial function in obesity/insulin resistance. Effects of troglitazone. Diabetologia. 1998 May;41(5):569-76. doi: 10.1007/s001250050948.
Results Reference
background
PubMed Identifier
9562340
Citation
Yki-Jarvinen H, Utriainen T. Insulin-induced vasodilatation: physiology or pharmacology? Diabetologia. 1998 Apr;41(4):369-79. doi: 10.1007/s001250050919. No abstract available.
Results Reference
background
PubMed Identifier
7586259
Citation
Taddei S, Virdis A, Mattei P, Natali A, Ferrannini E, Salvetti A. Effect of insulin on acetylcholine-induced vasodilation in normotensive subjects and patients with essential hypertension. Circulation. 1995 Nov 15;92(10):2911-8. doi: 10.1161/01.cir.92.10.2911.
Results Reference
background
PubMed Identifier
9697823
Citation
Bonadonna RC, Saccomani MP, Del Prato S, Bonora E, DeFronzo RA, Cobelli C. Role of tissue-specific blood flow and tissue recruitment in insulin-mediated glucose uptake of human skeletal muscle. Circulation. 1998 Jul 21;98(3):234-41. doi: 10.1161/01.cir.98.3.234.
Results Reference
background
PubMed Identifier
8083357
Citation
Steinberg HO, Brechtel G, Johnson A, Fineberg N, Baron AD. Insulin-mediated skeletal muscle vasodilation is nitric oxide dependent. A novel action of insulin to increase nitric oxide release. J Clin Invest. 1994 Sep;94(3):1172-9. doi: 10.1172/JCI117433.
Results Reference
background
PubMed Identifier
8997227
Citation
Baron AD, Brechtel-Hook G, Johnson A, Cronin J, Leaming R, Steinberg HO. Effect of perfusion rate on the time course of insulin-mediated skeletal muscle glucose uptake. Am J Physiol. 1996 Dec;271(6 Pt 1):E1067-72. doi: 10.1152/ajpendo.1996.271.6.E1067.
Results Reference
background
PubMed Identifier
14747297
Citation
Zhang L, Vincent MA, Richards SM, Clerk LH, Rattigan S, Clark MG, Barrett EJ. Insulin sensitivity of muscle capillary recruitment in vivo. Diabetes. 2004 Feb;53(2):447-53. doi: 10.2337/diabetes.53.2.447.
Results Reference
background
PubMed Identifier
17720897
Citation
Eggleston EM, Jahn LA, Barrett EJ. Hyperinsulinemia rapidly increases human muscle microvascular perfusion but fails to increase muscle insulin clearance: evidence that a saturable process mediates muscle insulin uptake. Diabetes. 2007 Dec;56(12):2958-63. doi: 10.2337/db07-0670. Epub 2007 Aug 24.
Results Reference
background
PubMed Identifier
17563063
Citation
Inyard AC, Clerk LH, Vincent MA, Barrett EJ. Contraction stimulates nitric oxide independent microvascular recruitment and increases muscle insulin uptake. Diabetes. 2007 Sep;56(9):2194-200. doi: 10.2337/db07-0020. Epub 2007 Jun 11.
Results Reference
background
PubMed Identifier
16644702
Citation
Clerk LH, Vincent MA, Jahn LA, Liu Z, Lindner JR, Barrett EJ. Obesity blunts insulin-mediated microvascular recruitment in human forearm muscle. Diabetes. 2006 May;55(5):1436-42. doi: 10.2337/db05-1373.
Results Reference
background
PubMed Identifier
12791603
Citation
Vincent MA, Barrett EJ, Lindner JR, Clark MG, Rattigan S. Inhibiting NOS blocks microvascular recruitment and blunts muscle glucose uptake in response to insulin. Am J Physiol Endocrinol Metab. 2003 Jul;285(1):E123-9. doi: 10.1152/ajpendo.00021.2003.
Results Reference
background
PubMed Identifier
17911341
Citation
Clerk LH, Vincent MA, Barrett EJ, Lankford MF, Lindner JR. Skeletal muscle capillary responses to insulin are abnormal in late-stage diabetes and are restored by angiotensin-converting enzyme inhibition. Am J Physiol Endocrinol Metab. 2007 Dec;293(6):E1804-9. doi: 10.1152/ajpendo.00498.2007. Epub 2007 Oct 2.
Results Reference
background
PubMed Identifier
10078557
Citation
Rattigan S, Clark MG, Barrett EJ. Acute vasoconstriction-induced insulin resistance in rat muscle in vivo. Diabetes. 1999 Mar;48(3):564-9. doi: 10.2337/diabetes.48.3.564.
Results Reference
background
PubMed Identifier
18347836
Citation
Lauer T, Heiss C, Balzer J, Kehmeier E, Mangold S, Leyendecker T, Rottler J, Meyer C, Merx MW, Kelm M, Rassaf T. Age-dependent endothelial dysfunction is associated with failure to increase plasma nitrite in response to exercise. Basic Res Cardiol. 2008 May;103(3):291-7. doi: 10.1007/s00395-008-0714-3. Epub 2008 Mar 17.
Results Reference
background
PubMed Identifier
18955635
Citation
Selvin E, Bolen S, Yeh HC, Wiley C, Wilson LM, Marinopoulos SS, Feldman L, Vassy J, Wilson R, Bass EB, Brancati FL. Cardiovascular outcomes in trials of oral diabetes medications: a systematic review. Arch Intern Med. 2008 Oct 27;168(19):2070-80. doi: 10.1001/archinte.168.19.2070.
Results Reference
background
PubMed Identifier
19996308
Citation
Agarwal N, Rice SP, Bolusani H, Luzio SD, Dunseath G, Ludgate M, Rees DA. Metformin reduces arterial stiffness and improves endothelial function in young women with polycystic ovary syndrome: a randomized, placebo-controlled, crossover trial. J Clin Endocrinol Metab. 2010 Feb;95(2):722-30. doi: 10.1210/jc.2009-1985. Epub 2009 Dec 8.
Results Reference
background
PubMed Identifier
20684955
Citation
Naka KK, Kalantaridou SN, Kravariti M, Bechlioulis A, Kazakos N, Calis KA, Makrigiannakis A, Katsouras CS, Chrousos GP, Tsatsoulis A, Michalis LK. Effect of the insulin sensitizers metformin and pioglitazone on endothelial function in young women with polycystic ovary syndrome: a prospective randomized study. Fertil Steril. 2011 Jan;95(1):203-9. doi: 10.1016/j.fertnstert.2010.06.058. Epub 2010 Aug 4.
Results Reference
background
PubMed Identifier
15265871
Citation
Zou MH, Kirkpatrick SS, Davis BJ, Nelson JS, Wiles WG 4th, Schlattner U, Neumann D, Brownlee M, Freeman MB, Goldman MH. Activation of the AMP-activated protein kinase by the anti-diabetic drug metformin in vivo. Role of mitochondrial reactive nitrogen species. J Biol Chem. 2004 Oct 15;279(42):43940-51. doi: 10.1074/jbc.M404421200. Epub 2004 Jul 19.
Results Reference
background
PubMed Identifier
18835932
Citation
Xie Z, Zhang J, Wu J, Viollet B, Zou MH. Upregulation of mitochondrial uncoupling protein-2 by the AMP-activated protein kinase in endothelial cells attenuates oxidative stress in diabetes. Diabetes. 2008 Dec;57(12):3222-30. doi: 10.2337/db08-0610. Epub 2008 Oct 3.
Results Reference
background
PubMed Identifier
15159266
Citation
Katzmarzyk PT, Church TS, Blair SN. Cardiorespiratory fitness attenuates the effects of the metabolic syndrome on all-cause and cardiovascular disease mortality in men. Arch Intern Med. 2004 May 24;164(10):1092-7. doi: 10.1001/archinte.164.10.1092.
Results Reference
background
PubMed Identifier
12750596
Citation
Allen JD, Geaghan JP, Greenway F, Welsch MA. Time course of improved flow-mediated dilation after short-term exercise training. Med Sci Sports Exerc. 2003 May;35(5):847-53. doi: 10.1249/01.MSS.0000064931.62916.8A.
Results Reference
background
PubMed Identifier
17027823
Citation
Sugawara J, Otsuki T, Tanabe T, Hayashi K, Maeda S, Matsuda M. Physical activity duration, intensity, and arterial stiffening in postmenopausal women. Am J Hypertens. 2006 Oct;19(10):1032-6. doi: 10.1016/j.amjhyper.2006.03.008.
Results Reference
background
PubMed Identifier
19022788
Citation
Miyaki A, Maeda S, Yoshizawa M, Misono M, Saito Y, Sasai H, Endo T, Nakata Y, Tanaka K, Ajisaka R. Effect of weight reduction with dietary intervention on arterial distensibility and endothelial function in obese men. Angiology. 2009 Jun-Jul;60(3):351-7. doi: 10.1177/0003319708325449. Epub 2008 Nov 19.
Results Reference
background

Learn more about this trial

Effect of Metformin on Insulin Sensitivity and Pan-Arterial Vascular Function in Adults With Metabolic Syndrome

We'll reach out to this number within 24 hrs